India Approves Novo Nordisk's Obesity Drug Wegovy for Fatty Liver Disease

India's regulatory authority has approved Novo Nordisk's popular obesity drug Wegovy (semaglutide) for the treatment of a specific type of fatty liver disease. This decision expands the drug's usage, highlighting its potential in addressing metabolic health issues. According to Reuters, the approval allows Wegovy to be used in patients with obesity-related liver steatosis, a condition also known as non-alcoholic steatohepatitis (NASH), which can lead to inflammation and liver damage. Novo Nordisk stated that the approval of Wegovy for this new indication will strengthen the company's leadership in metabolic diseases. Previously used solely for weight management, clinical studies have shown positive effects on liver health as well. India is among countries grappling with rising obesity and related liver diseases. This approval offers a new treatment option for both obesity and NASH in the country. This is not investment advice.

📊 NVO — Piyasa Yorumu

▲ up · 65%

The news expands the potential market for Novo Nordisk's obesity drug portfolio with the approval of Wegovy for a new indication. Technical indicators show the stock is in a short-term uptrend, with the RSI not yet approaching overbought territory. The MACD line is above the signal line and in positive territory, suggesting momentum may continue. However, the 4.77% rise in the last 24 hours and the RSI at 68 also bring some risk of profit-taking in the short term. Overall, the positive impact of the news and the strength of the technical structure support an upward movement in the near term.

RSI 14

67.8

MACD

0.59

24h Δ

4.77%

📊 GOOGL — Piyasa Yorumu

■ neutral · 30%

The news does not have a direct impact on GOOGL, as the company has no direct presence in the obesity drug market. Technical indicators suggest the stock is in short-term weakness: the RSI is near oversold territory at 35, and the price is trading below both the 20-day and 50-day moving averages. The MACD is below the signal line and moving into negative territory, indicating weakening momentum. However, direction remains uncertain due to the oversold signal, which may limit further downside, and the neutral impact of the news.

RSI 14

35.0

MACD

0.62

24h Δ

-0.39%

Canlı Grafikler